Adc Therapeutics SA 8-K filings

ADC Therapeutics reported Q2 2026 financial results with $18.6M in net product revenue, but faces FDA concerns over LOTIS-5 trial data and announced a 17% workforce reduction.

ADC Therapeutics SA announced on June 30, 2026, the approval of one-time retention awards for certain employees, including named executive officers, comprising cash incentives and Restricted Stock Units (RSUs).

ADC Therapeutics is cutting 17% of its global workforce to streamline operations and focus resources on ZYNLONTA clinical milestones.

ADC Therapeutics announced topline data from its Phase 3 LOTIS-5 trial, showing ZYNLONTA in combination with rituximab met its primary endpoint for progression-free survival in relapsed or refractory diffuse large B-cell lymphoma.

ADC Therapeutics SA announced that all proposals submitted to shareholders at its 2026 annual general meeting on June 1, 2026, were approved, including financial statements and director reelections.

ADC Therapeutics reported first quarter 2026 net product revenue of $20.0 million, an increase from the prior year, while net loss narrowed to $33.0 million, driven by lower operating expenses.

ADC Therapeutics SA has amended its royalty agreement with HealthCare Royalty Management, LLC, revising change of control payments and issuing warrants for 9.8 million common shares.

ADC Therapeutics SA provides an updated corporate presentation detailing ZYNLONTA's clinical progress, strategic reprioritization, and financial position with an expected cash runway to at least 2028.

ADC Therapeutics announced preliminary 2025 financial results, including increased ZYNLONTA revenue and an extended cash runway, alongside key clinical trial updates.

ADC Therapeutics announced updated positive data from its LOTIS-7 Phase 1b clinical trial for ZYNLONTA in combination with glofitamab for relapsed or refractory DLBCL.

ADC Therapeutics announced its third quarter 2025 financial results, highlighting progress in its ZYNLONTA clinical trials and a strengthened balance sheet from a recent $60 million PIPE financing.

ADC Therapeutics SA announced a $60 million private placement and preliminary Q3 2025 financial results, alongside promising clinical data for ZYNLONTA in various lymphoma indications.

ADC Therapeutics SA released an updated corporate presentation detailing strong clinical data for ZYNLONTA in lymphoma and outlining a cash runway into 2028.

ADC Therapeutics announced its second quarter 2025 financial results, highlighted by strong ZYNLONTA clinical data, a $100 million PIPE financing extending cash runway into 2028, and a strategic restructuring.

ADC Therapeutics SA has entered into a $100 million private placement to bolster its financial position and simultaneously announced a strategic restructuring plan, including a 30% global workforce reduction and the closure of its U.K. R&D facility, to focus on key oncology programs.

ADC Therapeutics SA announced that its shareholders approved all proposals at the 2025 Annual General Meeting, including financial statements, executive compensation, director elections, and significant amendments to the company's articles of association.

ADC Therapeutics announced its Q1 2025 financial results, highlighting the potential of ZYNLONTA in combination with glofitamab and providing updates on its clinical trials and preclinical programs.

ADC Therapeutics announced its fourth quarter and full year 2024 financial results, showcasing progress with ZYNLONTA and providing operational updates.

ADC Therapeutics released preliminary information on ZYNLONTA sales and expenses for 2024, along with updates on clinical trials and future strategic goals.

ADC Therapeutics shareholders voted to approve amendments to the company's articles of association, increasing its capital range and conditional share capital.

ADC Therapeutics announced its third quarter 2024 financial results, provided operational updates, and highlighted the discontinuation of the ADCT-601 program.

ADC Therapeutics reports ZYNLONTA achieved commercial profitability in the first half of 2024, with $17.0 million in net sales for the second quarter, and provides updates on clinical trials.

ADC Therapeutics successfully held its 2024 annual general meeting, with shareholders approving all submitted proposals, including the re-election of directors and compensation committee members.

ADC Therapeutics provides an update on its clinical programs, financial strategy, and research pipeline, emphasizing its focus on hematology and solid tumor treatments.

ADC Therapeutics has completed a $105 million offering, issuing common shares and pre-funded warrants.

ADC Therapeutics announced encouraging initial Phase 2 clinical trial data for ZYNLONTA in relapsed/refractory marginal zone lymphoma and reported first quarter 2024 financial results with a focus on hematology and pipeline advancement.

ADC Therapeutics presented updates on its research strategy, highlighting a novel exatecan-based antibody drug conjugate platform and its lead candidates at a virtual investor event.

ADC Therapeutics reported its full year 2023 financial results, showcasing a decrease in operating expenses and progress in its clinical pipeline, including ZYNLONTA sales growth in the fourth quarter.

ADC Therapeutics shared a business overview, highlighting clinical trial progress, financial status, and strategic priorities, with a cash runway extending into the fourth quarter of 2025.

ADC Therapeutics SA has approved a new cash-based annual incentive plan to reward employees based on the company's achievement of corporate objectives.